首页 > 最新文献

Scandinavian Cardiovascular Journal最新文献

英文 中文
The association between GRACE score at admission for myocardial infarction and the incidence of sudden cardiac arrests in long-term follow-up - the MADDEC study. 心肌梗死入院时的 GRACE 评分与长期随访中心脏骤停发生率之间的关系 - MADDEC 研究。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-04-01 DOI: 10.1080/14017431.2024.2335905
Markus Hautamäki, Minna Järvensivu-Koivunen, Leo-Pekka Lyytikäinen, Markku Eskola, Terho Lehtimäki, Kjell Nikus, Niku Oksala, Juho Tynkkynen, Jussi Hernesniemi

Background. Sudden cardiac arrest (SCA), often also leading to sudden cardiac death (SCD), is a common complication in coronary artery disease. Despite the effort there is a lack of applicable prediction tools to identify those at high risk. We tested the association between the validated GRACE score and the incidence of SCA after myocardial infarction. Material and methods. A retrospective analysis of 1,985 patients treated for myocardial infarction (MI) between January 1st 2015 and December 31st 2018 and followed until the 31st of December of 2021. The main exposure variable was patients' GRACE score at the point of admission and main outcome variable was incident SCA after hospitalization. Their association was analyzed by subdistribution hazard (SDH) model analysis. The secondary endpoints included SCA in patients with no indication to implantable cardioverter-defibrillator (ICD) device and incident SCD. Results. A total of 1985 patients were treated for MI. Mean GRACE score at baseline was 118.7 (SD 32.0). During a median follow-up time of 5.3 years (IQR 3.8-6.1 years) 78 SCA events and 52 SCDs occurred. In unadjusted analyses one SD increase in GRACE score associated with over 50% higher risk of SCA (SDH 1.55, 95% CI 1.29-1.85, p < 0.0001) and over 40% higher risk for SCD (1.42, 1.12-1.79, p = 0.0033). The associations between SCA and GRACE remained statistically significant even with patients without indication for ICD device (1.57, 1.30-1.90, p < 0.0001) as well as when adjusting with patients LVEF and omitting the age from the GRACE score to better represent the severity of the cardiac event. The association of GRACE and SCD turned statistically insignificant when adjusting with LVEF. Conclusions. GRACE score measured at admission for MI associates with long-term risk for SCA.

背景。心脏骤停(SCA)通常也会导致心脏性猝死(SCD),是冠心病的常见并发症。尽管已经做出了努力,但仍缺乏适用的预测工具来识别高危人群。我们测试了经过验证的 GRACE 评分与心肌梗死后 SCA 发生率之间的关联。材料和方法对2015年1月1日至2018年12月31日期间接受心肌梗死(MI)治疗并随访至2021年12月31日的1985名患者进行回顾性分析。主要暴露变量是患者入院时的 GRACE 评分,主要结局变量是住院后发生的 SCA。它们之间的关系通过亚分布危险(SDH)模型分析得出。次要终点包括无植入式心律转复除颤器(ICD)装置指征的患者的SCA和偶发SCD。结果共有1985名心肌梗死患者接受了治疗。基线时的平均 GRACE 评分为 118.7(标准差为 32.0)。中位随访时间为 5.3 年(IQR 3.8-6.1 年),共发生 78 例 SCA 事件和 52 例 SCD。在未经调整的分析中,GRACE 评分每增加 1 SD,SCA 风险就会增加 50%(SDH 1.55,95% CI 1.29-1.85,P = 0.0033)。即使是无 ICD 装置指征的患者,SCA 与 GRACE 之间的关系仍具有统计学意义(1.57, 1.30-1.90, p 结论:GRACE 评分越高,SCA 风险越高。心肌梗死入院时的 GRACE 评分与 SCA 的长期风险有关。
{"title":"The association between GRACE score at admission for myocardial infarction and the incidence of sudden cardiac arrests in long-term follow-up - the MADDEC study.","authors":"Markus Hautamäki, Minna Järvensivu-Koivunen, Leo-Pekka Lyytikäinen, Markku Eskola, Terho Lehtimäki, Kjell Nikus, Niku Oksala, Juho Tynkkynen, Jussi Hernesniemi","doi":"10.1080/14017431.2024.2335905","DOIUrl":"10.1080/14017431.2024.2335905","url":null,"abstract":"<p><p><i>Background.</i> Sudden cardiac arrest (SCA), often also leading to sudden cardiac death (SCD), is a common complication in coronary artery disease. Despite the effort there is a lack of applicable prediction tools to identify those at high risk. We tested the association between the validated GRACE score and the incidence of SCA after myocardial infarction. <i>Material and methods.</i> A retrospective analysis of 1,985 patients treated for myocardial infarction (MI) between January 1st 2015 and December 31st 2018 and followed until the 31st of December of 2021. The main exposure variable was patients' GRACE score at the point of admission and main outcome variable was incident SCA after hospitalization. Their association was analyzed by subdistribution hazard (SDH) model analysis. The secondary endpoints included SCA in patients with no indication to implantable cardioverter-defibrillator (ICD) device and incident SCD. <i>Results.</i> A total of 1985 patients were treated for MI. Mean GRACE score at baseline was 118.7 (SD 32.0). During a median follow-up time of 5.3 years (IQR 3.8-6.1 years) 78 SCA events and 52 SCDs occurred. In unadjusted analyses one SD increase in GRACE score associated with over 50% higher risk of SCA (SDH 1.55, 95% CI 1.29-1.85, <i>p</i> < 0.0001) and over 40% higher risk for SCD (1.42, 1.12-1.79, <i>p</i> = 0.0033). The associations between SCA and GRACE remained statistically significant even with patients without indication for ICD device (1.57, 1.30-1.90, <i>p</i> < 0.0001) as well as when adjusting with patients LVEF and omitting the age from the GRACE score to better represent the severity of the cardiac event. The association of GRACE and SCD turned statistically insignificant when adjusting with LVEF. <i>Conclusions.</i> GRACE score measured at admission for MI associates with long-term risk for SCA.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2335905"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Nordic countries 30-day mortality rate is half that estimated with EuroSCORE II in high-risk adult patients given aprotinin and undergoing mainly complex cardiac procedures. 在北欧国家,主要接受复杂心脏手术的高危成人患者服用阿普罗宁后,30 天的死亡率仅为 EuroSCORE II 估计死亡率的一半。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-03-31 DOI: 10.1080/14017431.2024.2330347
Jan van der Linden, Thomas Fux, Timo Kaakinen, Juha Rutanen, Jenni M Toivonen, Fredrik Nyström, Alexander Wahba, Bengt Hammas, Maria Parviainen, Doris Cunha-Goncalves, Seppo Hiippala

Objectives. To describe current on- (isolated coronary arterty bypass grafting, iCABG) and off-label (non-iCABG) use of aprotinin and associated safety endpoints in adult patients undergoing high-risk cardiac surgery in Nordic countries. Design. Data come from 10 cardiac surgery centres in Finland, Norway and Sweden participating in the European Nordic aprotinin patient registry (NAPaR). Results. 486 patients were given aprotinin between 2016 and 2020. 59 patients (12.1%) underwent iCABG and 427 (87.9%) non-iCABG, including surgery for aortic dissection (16.7%) and endocarditis (36.0%). 89.9% were administered a full aprotinin dosage and 37.0% were re-sternotomies. Dual antiplatelet treatment affected 72.9% of iCABG and 7.0% of non-iCABG patients. 0.6% of patients had anaphylactic reactions associated with aprotinin. 6.4% (95 CI% 4.2%-8.6%) of patients were reoperated for bleeding. Rate of postoperative thromboembolic events, day 1 rise in creatinine >44μmol/L and new dialysis for any reason was 4.7% (95%CI 2.8%-6.6%), 16.7% (95%CI 13.4%-20.0%) and 14.0% (95%CI 10.9%-17.1%), respectively. In-hospital mortality and 30-day mortality was 4.9% (95%CI 2.8%-6.9%) and 6.3% (95%CI 3.7%-7.8%) in all patients versus mean EuroSCORE II 11.4% (95%CI 8.4%-14.0%, p < .01). 30-day mortality in patients undergoing surgery for aortic dissection and endocarditis was 6.2% (95%CI 0.9%-11.4%) and 6.3% (95%CI 2.7%-9.9%) versus mean EuroSCORE II 13.2% (95%CI 6.1%-21.0%, p = .11) and 14.5% (95%CI 12.1%-16.8%, p = .01), respectively. Conclusions. NAPaR data from Nordic countries suggest a favourable safety profile of aprotinin in adult cardiac surgery.

目的描述北欧国家目前在接受高风险心脏手术的成年患者中,杏仁蛋白的标签内(孤立冠状动脉旁路移植术,iCABG)和标签外(非 iCABG)使用情况以及相关的安全性终点。设计。数据来自芬兰、挪威和瑞典参加欧洲北欧杏仁蛋白患者登记处(NAPaR)的 10 个心脏外科中心。结果。2016年至2020年间,486名患者接受了阿普罗宁治疗。59名患者(12.1%)接受了iCABG手术,427名患者(87.9%)接受了非iCABG手术,包括主动脉夹层(16.7%)和心内膜炎(36.0%)手术。89.9%的患者接受了全量阿普罗宁治疗,37.0%的患者接受了再梗死手术。72.9%的 iCABG 患者和 7.0% 的非 iCABG 患者接受了双重抗血小板治疗。0.6%的患者出现了与阿普罗宁相关的过敏反应。6.4%(95 CI% 4.2%-8.6%)的患者因出血而再次手术。术后血栓栓塞事件、第1天血肌酐升高>44μmol/L和因任何原因再次透析的比例分别为4.7%(95%CI 2.8%-6.6%)、16.7%(95%CI 13.4%-20.0%)和14.0%(95%CI 10.9%-17.1%)。所有患者的院内死亡率和 30 天死亡率分别为 4.9% (95%CI 2.8%-6.9%) 和 6.3% (95%CI 3.7%-7.8%) ,而 EuroSCORE II 平均值分别为 11.4% (95%CI 8.4%-14.0%, p p = .11) 和 14.5% (95%CI 12.1%-16.8%, p = .01)。结论北欧国家的 NAPaR 数据表明,阿普罗宁在成人心脏手术中具有良好的安全性。
{"title":"In Nordic countries 30-day mortality rate is half that estimated with EuroSCORE II in high-risk adult patients given aprotinin and undergoing mainly complex cardiac procedures.","authors":"Jan van der Linden, Thomas Fux, Timo Kaakinen, Juha Rutanen, Jenni M Toivonen, Fredrik Nyström, Alexander Wahba, Bengt Hammas, Maria Parviainen, Doris Cunha-Goncalves, Seppo Hiippala","doi":"10.1080/14017431.2024.2330347","DOIUrl":"10.1080/14017431.2024.2330347","url":null,"abstract":"<p><p><i>Objectives.</i> To describe current on- (isolated coronary arterty bypass grafting, iCABG) and off-label (non-iCABG) use of aprotinin and associated safety endpoints in adult patients undergoing high-risk cardiac surgery in Nordic countries. <i>Design.</i> Data come from 10 cardiac surgery centres in Finland, Norway and Sweden participating in the European Nordic aprotinin patient registry (NAPaR). <i>Results.</i> 486 patients were given aprotinin between 2016 and 2020. 59 patients (12.1%) underwent iCABG and 427 (87.9%) non-iCABG, including surgery for aortic dissection (16.7%) and endocarditis (36.0%). 89.9% were administered a full aprotinin dosage and 37.0% were re-sternotomies. Dual antiplatelet treatment affected 72.9% of iCABG and 7.0% of non-iCABG patients. 0.6% of patients had anaphylactic reactions associated with aprotinin. 6.4% (95 CI% 4.2%-8.6%) of patients were reoperated for bleeding. Rate of postoperative thromboembolic events, day 1 rise in creatinine >44μmol/L and new dialysis for any reason was 4.7% (95%CI 2.8%-6.6%), 16.7% (95%CI 13.4%-20.0%) and 14.0% (95%CI 10.9%-17.1%), respectively. In-hospital mortality and 30-day mortality was 4.9% (95%CI 2.8%-6.9%) and 6.3% (95%CI 3.7%-7.8%) in all patients versus mean EuroSCORE II 11.4% (95%CI 8.4%-14.0%, <i>p</i> < .01). 30-day mortality in patients undergoing surgery for aortic dissection and endocarditis was 6.2% (95%CI 0.9%-11.4%) and 6.3% (95%CI 2.7%-9.9%) versus mean EuroSCORE II 13.2% (95%CI 6.1%-21.0%, <i>p</i> = .11) and 14.5% (95%CI 12.1%-16.8%, <i>p</i> = .01), respectively. <i>Conclusions.</i> NAPaR data from Nordic countries suggest a favourable safety profile of aprotinin in adult cardiac surgery.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2330347"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of normal body mass index and weight loss with long-term major cardiovascular events after PCI for myocardial infarction. 正常体重指数和体重减轻与 PCI 治疗心肌梗死后长期主要心血管事件的关系。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-08-06 DOI: 10.1080/14017431.2024.2386984
Jan Erik Otterstad, John Munkhaugen, Vidar Ruddox, Thor Edvardsen, Jøran Hjelmesæth

Objectives: To investigate whether normal body mass index (BMI) shortly after percutaneous coronary intervention (PCI) for myocardial infarction is associated with increased risk of long-term major cardiovascular events (MACE), and to explore potential clinical determinants of long-term weight loss (WL) after PCI. Methods: Single-center cohort study with 5-year follow-up of patients treated with PCI for myocardial infarction between 2016 and 2018. Categorical WL was defined as > 0 kg body weight reduction from baseline to end of follow-up. Results: Of 236 patients (24% women), mean age was 64.9 ± 10.2 years and mean BMI within 4 days after PCI was 27.1 ± 4.3 kg/m2. Seventy-five patients (32%) had at least one MACE, equally distributed between those with normal weight (31%), overweight (32%), and obesity (31%). Patients with overweight or obesity had a lower crude mortality rate than their normal weight counterparts (7.4% vs 16.4%, p = 0.049), but the relative hazard of death did not differ from those with normal weight, HR 0.50, 95% CI 0.22-1.15. Patients with either a long-term WL (n = 112) or no WL (n = 95) had a comparable incidence of non-fatal MACE (27% vs 22%, p = 0.518). The proportion of patients reporting unintentional weight loss was significantly higher in the normal weight group (82%) compared with those with overweight (41%) or obesity (28%), p < 0.001. Conclusion: Our results did not confirm any association between normal BMI after PCI and long-term MACE. However, patients with normal BMI at baseline had a higher incidence of unintentional WL than those with elevated BMI. Trial registration: Current research information system in Norway (CRISTIN): ID 542528.

目的研究心肌梗死经皮冠状动脉介入治疗(PCI)后短期内体重指数(BMI)正常是否与长期主要心血管事件(MACE)风险增加有关,并探讨PCI后长期体重减轻(WL)的潜在临床决定因素。方法:单中心队列研究对2016年至2018年间接受PCI治疗的心肌梗死患者进行为期5年的单中心队列研究。从基线到随访结束,体重减轻>0 kg定义为分类减重。结果显示236名患者(24%为女性)的平均年龄为(64.9±10.2)岁,PCI术后4天内的平均体重指数为(27.1±4.3)千克/平方米。75名患者(32%)至少有一次MACE,体重正常(31%)、超重(32%)和肥胖(31%)的患者比例相当。超重或肥胖患者的粗死亡率低于体重正常的患者(7.4% vs 16.4%,P = 0.049),但死亡的相对危险性与体重正常的患者没有差异,HR 为 0.50,95% CI 为 0.22-1.15。长期WL(n = 112)或无WL(n = 95)的患者的非致死性MACE发生率相当(27% vs 22%,p = 0.518)。与超重(41%)或肥胖(28%)患者相比,体重正常组(82%)报告无意减轻体重的患者比例明显较高,P 结论:我们的结果并未证实体重正常组与超重组或肥胖组之间存在任何关联:我们的研究结果并未证实PCI术后体重指数正常与长期MACE之间存在任何关联。然而,基线体重指数正常的患者比体重指数升高的患者有更高的无意WL发生率。试验注册:挪威当前研究信息系统(CRISTIN):ID 542528。
{"title":"Association of normal body mass index and weight loss with long-term major cardiovascular events after PCI for myocardial infarction.","authors":"Jan Erik Otterstad, John Munkhaugen, Vidar Ruddox, Thor Edvardsen, Jøran Hjelmesæth","doi":"10.1080/14017431.2024.2386984","DOIUrl":"10.1080/14017431.2024.2386984","url":null,"abstract":"<p><p><i>Objectives:</i> To investigate whether normal body mass index (BMI) shortly after percutaneous coronary intervention (PCI) for myocardial infarction is associated with increased risk of long-term major cardiovascular events (MACE), and to explore potential clinical determinants of long-term weight loss (WL) after PCI. <i>Methods:</i> Single-center cohort study with 5-year follow-up of patients treated with PCI for myocardial infarction between 2016 and 2018. Categorical WL was defined as > 0 kg body weight reduction from baseline to end of follow-up. <i>Results:</i> Of 236 patients (24% women), mean age was 64.9 ± 10.2 years and mean BMI within 4 days after PCI was 27.1 ± 4.3 kg/m<sup>2</sup>. Seventy-five patients (32%) had at least one MACE, equally distributed between those with normal weight (31%), overweight (32%), and obesity (31%). Patients with overweight or obesity had a lower crude mortality rate than their normal weight counterparts (7.4% vs 16.4%, <i>p</i> = 0.049), but the relative hazard of death did not differ from those with normal weight, HR 0.50, 95% CI 0.22-1.15. Patients with either a long-term WL (<i>n</i> = 112) or no WL (<i>n</i> = 95) had a comparable incidence of non-fatal MACE (27% vs 22%, <i>p</i> = 0.518). The proportion of patients reporting unintentional weight loss was significantly higher in the normal weight group (82%) compared with those with overweight (41%) or obesity (28%), <i>p</i> < 0.001. <i>Conclusion:</i> Our results did not confirm any association between normal BMI after PCI and long-term MACE. However, patients with normal BMI at baseline had a higher incidence of unintentional WL than those with elevated BMI. Trial registration: Current research information system in Norway (CRISTIN): ID 542528.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2386984"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A reply to the letter to the editor "Management of bifurcation lesions with active side branch protection strategies". 回复致编辑的信 "采用主动侧支保护策略管理分叉病变"。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-08-09 DOI: 10.1080/14017431.2024.2389901
Jiuchun Qiu, Longyan Li, Weiding Wang, Xinjian Li, Zizhao Zhang, Shuai Shao, Gary Tse, Guangping Li, Tong Liu
{"title":"A reply to the letter to the editor \"Management of bifurcation lesions with active side branch protection strategies\".","authors":"Jiuchun Qiu, Longyan Li, Weiding Wang, Xinjian Li, Zizhao Zhang, Shuai Shao, Gary Tse, Guangping Li, Tong Liu","doi":"10.1080/14017431.2024.2389901","DOIUrl":"10.1080/14017431.2024.2389901","url":null,"abstract":"","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2389901"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141913769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single center outcomes after temporary mechanical circulatory assist device prior to Heartmate 3 implantation - a retrospective cohort study. 在植入 Heartmate 3 之前使用临时机械循环辅助装置后的单中心结果 - 一项回顾性队列研究。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-07-04 DOI: 10.1080/14017431.2024.2353066
Imran Jamal Iversen, Finn Gustafsson, Kasper Rossing, Peter Hasse Møller-Sørensen, Peter Skov Olsen, Christian Holdflod Møller

Objectives. Temporary mechanical circulatory support (TMCS) has become a component in the therapeutic strategy for treatment of cardiogenic shock as a bridge-to-decision. TMCS can facilitate recovery of cardiopulmonary function, end-organ function, and potentially reduce the surgical risk of left ventricular assist device (LVAD) implantation. Despite the improvements of hemodynamics and end-organ function, post-LVAD operative morbidity might be increased in these high-risk patients. The aim of the study was to compare outcomes after Heartmate 3 (HM3) implantation in patients with and without TMCS prior to HM3 implant. Methods. In this retrospective cohort study of all HM3 patients in the period between November 2015 and October 2021, patients with and without prior TMCS were compared. Patients' demographics, baseline clinical characteristics, laboratory tests, intraoperative variables, postoperative outcomes, and adverse events were collected from patient records. Results. The TMCS group showed an improvement in hemodynamics prior to LVAD implantation. Median TMCS duration was 19.5 (14-26) days. However, the TMCS group were more coagulopathic, had more wound infections, neurological complications, and more patients were on dialysis compared with patient without TMCS prior to HM3 implantation. Survival four years after HM3 implantation was 80 and 82% in the TMCS (N = 22) and non-TMCS group (N = 41), respectively. Conclusion. Patients on TMCS had an acceptable short and long-term survival and comparable to patients receiving HM3 without prior TMCS. However, they had a more complicated postoperative course.

目的。临时机械循环支持(TMCS)已成为治疗心源性休克的治疗策略中的一个组成部分,是决定性的桥梁。临时机械循环支持可促进心肺功能和内脏器官功能的恢复,并有可能降低植入左心室辅助装置(LVAD)的手术风险。尽管血液动力学和内脏器官功能有所改善,但在这些高风险患者中,LVAD 术后发病率可能会增加。本研究的目的是比较在 HM3 植入前使用和未使用 TMCS 的患者植入 Heartmate 3(HM3)后的疗效。研究方法在这项回顾性队列研究中,对 2015 年 11 月至 2021 年 10 月期间的所有 HM3 患者进行了比较。研究人员从患者病历中收集了患者的人口统计学特征、基线临床特征、实验室检查、术中变量、术后结果和不良事件。结果显示TMCS 组患者在植入 LVAD 前血液动力学有所改善。中位 TMCS 持续时间为 19.5(14-26)天。然而,与 HM3 植入前未使用 TMCS 的患者相比,TMCS 组患者更容易发生凝血病变、伤口感染和神经系统并发症,而且更多患者需要接受透析治疗。植入 HM3 四年后,TMCS 组(22 人)和非 TMCS 组(41 人)的存活率分别为 80% 和 82%。结论TMCS患者的短期和长期存活率均可接受,与未接受TMCS的HM3患者不相上下。不过,他们的术后病程更为复杂。
{"title":"Single center outcomes after temporary mechanical circulatory assist device prior to Heartmate 3 implantation - a retrospective cohort study.","authors":"Imran Jamal Iversen, Finn Gustafsson, Kasper Rossing, Peter Hasse Møller-Sørensen, Peter Skov Olsen, Christian Holdflod Møller","doi":"10.1080/14017431.2024.2353066","DOIUrl":"10.1080/14017431.2024.2353066","url":null,"abstract":"<p><p><i>Objectives</i>. Temporary mechanical circulatory support (TMCS) has become a component in the therapeutic strategy for treatment of cardiogenic shock as a bridge-to-decision. TMCS can facilitate recovery of cardiopulmonary function, end-organ function, and potentially reduce the surgical risk of left ventricular assist device (LVAD) implantation. Despite the improvements of hemodynamics and end-organ function, post-LVAD operative morbidity might be increased in these high-risk patients. The aim of the study was to compare outcomes after Heartmate 3 (HM3) implantation in patients with and without TMCS prior to HM3 implant. <i>Methods.</i> In this retrospective cohort study of all HM3 patients in the period between November 2015 and October 2021, patients with and without prior TMCS were compared. Patients' demographics, baseline clinical characteristics, laboratory tests, intraoperative variables, postoperative outcomes, and adverse events were collected from patient records. <i>Results.</i> The TMCS group showed an improvement in hemodynamics prior to LVAD implantation. Median TMCS duration was 19.5 (14-26) days. However, the TMCS group were more coagulopathic, had more wound infections, neurological complications, and more patients were on dialysis compared with patient without TMCS prior to HM3 implantation. Survival four years after HM3 implantation was 80 and 82% in the TMCS (<i>N</i> = 22) and non-TMCS group (<i>N</i> = 41), respectively. <i>Conclusion</i>. Patients on TMCS had an acceptable short and long-term survival and comparable to patients receiving HM3 without prior TMCS. However, they had a more complicated postoperative course.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2353066"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining the impact of renal dysfunction and diabetes on post-myocardial infarction mortality: insights from a comprehensive retrospective cohort study across different age groups. 探讨肾功能障碍和糖尿病对心肌梗死后死亡率的影响:一项跨年龄组的全面回顾性队列研究的启示。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-08-28 DOI: 10.1080/14017431.2024.2395875
Piret Asser, Krista Fischer, Tiia Ainla, Toomas Marandi, Mai Blöndal, Aet Saar, Jaan Eha

Aim. Chronic kidney disease (CKD) and diabetes mellitus (DM) contribute significantly to cardiovascular disease (CVD) and mortality, with prevalence increasing. The evolving demographic of myocardial infarction (MI) patients, influenced by sedentary lifestyles and advanced medical care, lacks understanding regarding the interplay of CKD, DM, age, and post-MI mortality. This study aims to address this gap by evaluating the long-term impact of CKD and DM on post-MI mortality across age groups. Methods. A retrospective cohort study utilized data from the Estonian Myocardial Infarction Registry (EMIR), Estonian Population Register (EPR), and six major hospitals in Estonia, covering AMI hospitalizations from 2012 to 2019. Statistical analyses included Cox proportional hazards regression models and Kaplan-Meier's curves. Results. Analysis of 17,085 MI patients revealed age-dependent associations between renal function and mortality. In patients <65 years, even minor decreases in renal function increased both short-term (HR 2.79, 95% CI 1.71-4.55) and long-term (HR 1.24, 95% CI 1.05-1.47) mortality. Mortality significantly increased in patients >80 years only below an estimated glomerular filtration rate (eGFR) of 44 ml/min/1.73 m2. Newly diagnosed DM patients exhibited higher mortality rates (average HR 1.53, 95% CI 1.45-1.62), while pre-DM did not significantly differ from non-DM patients across all age groups. The DM-renal failure interaction did not significantly influence mortality. Conclusions. An age-dependent association between eGFR and post-MI outcomes emphasizes the need for personalized therapeutic approaches considering age-specific eGFR thresholds and comorbidities to optimize patient management.

目的:慢性肾脏病(CKD)和糖尿病(DM慢性肾脏病(CKD)和糖尿病(DM)是导致心血管疾病(CVD)和死亡率的重要因素,其发病率还在不断上升。受久坐不动的生活方式和先进医疗技术的影响,心肌梗塞(MI)患者的人口结构不断变化,但人们对慢性肾脏病、糖尿病、年龄和心肌梗塞后死亡率之间的相互作用缺乏了解。本研究旨在通过评估慢性肾脏病和糖尿病对不同年龄组心肌梗死后死亡率的长期影响来弥补这一不足。方法。一项回顾性队列研究利用了爱沙尼亚心肌梗死登记处(EMIR)、爱沙尼亚人口登记处(EPR)和爱沙尼亚六家主要医院的数据,涵盖了2012年至2019年的急性心肌梗死住院病例。统计分析包括 Cox 比例危险回归模型和 Kaplan-Meier 曲线。结果对17085名心肌梗死患者的分析显示,肾功能与死亡率之间存在年龄依赖关系。仅80岁以下患者的估计肾小球滤过率(eGFR)为44毫升/分钟/1.73平方米。新诊断的糖尿病患者死亡率较高(平均 HR 1.53,95% CI 1.45-1.62),而在所有年龄组中,糖尿病前期患者与非糖尿病患者没有明显差异。糖尿病与肾功能衰竭的交互作用对死亡率没有明显影响。结论eGFR与心肌梗死后的预后之间存在年龄依赖关系,这强调了个性化治疗方法的必要性,即考虑特定年龄的eGFR阈值和合并症,以优化患者管理。
{"title":"Examining the impact of renal dysfunction and diabetes on post-myocardial infarction mortality: insights from a comprehensive retrospective cohort study across different age groups.","authors":"Piret Asser, Krista Fischer, Tiia Ainla, Toomas Marandi, Mai Blöndal, Aet Saar, Jaan Eha","doi":"10.1080/14017431.2024.2395875","DOIUrl":"10.1080/14017431.2024.2395875","url":null,"abstract":"<p><p><i>Aim</i>. Chronic kidney disease (CKD) and diabetes mellitus (DM) contribute significantly to cardiovascular disease (CVD) and mortality, with prevalence increasing. The evolving demographic of myocardial infarction (MI) patients, influenced by sedentary lifestyles and advanced medical care, lacks understanding regarding the interplay of CKD, DM, age, and post-MI mortality. This study aims to address this gap by evaluating the long-term impact of CKD and DM on post-MI mortality across age groups. <i>Methods</i>. A retrospective cohort study utilized data from the Estonian Myocardial Infarction Registry (EMIR), Estonian Population Register (EPR), and six major hospitals in Estonia, covering AMI hospitalizations from 2012 to 2019. Statistical analyses included Cox proportional hazards regression models and Kaplan-Meier's curves. <i>Results</i>. Analysis of 17,085 MI patients revealed age-dependent associations between renal function and mortality. In patients <65 years, even minor decreases in renal function increased both short-term (HR 2.79, 95% CI 1.71-4.55) and long-term (HR 1.24, 95% CI 1.05-1.47) mortality. Mortality significantly increased in patients >80 years only below an estimated glomerular filtration rate (eGFR) of 44 ml/min/1.73 m<sup>2</sup>. Newly diagnosed DM patients exhibited higher mortality rates (average HR 1.53, 95% CI 1.45-1.62), while pre-DM did not significantly differ from non-DM patients across all age groups. The DM-renal failure interaction did not significantly influence mortality. <i>Conclusions</i>. An age-dependent association between eGFR and post-MI outcomes emphasizes the need for personalized therapeutic approaches considering age-specific eGFR thresholds and comorbidities to optimize patient management.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2395875"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five basic rules for making non-inferiority trials more meaningful. 使非劣效试验更有意义的五项基本规则。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI: 10.1080/14017431.2024.2374391
Björn Redfors
{"title":"Five basic rules for making non-inferiority trials more meaningful.","authors":"Björn Redfors","doi":"10.1080/14017431.2024.2374391","DOIUrl":"10.1080/14017431.2024.2374391","url":null,"abstract":"","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2374391"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum microRNA-125b-5p expression in patients with dilated cardiomyopathy combined with heart failure and its effect on myocardial fibrosis. 扩张型心肌病合并心力衰竭患者血清 microRNA-125b-5p 的表达及其对心肌纤维化的影响
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2024-07-18 DOI: 10.1080/14017431.2024.2373083
Yingjie Zhang, Daqing Deng, Quan Huang, Jiaru Wu, Yi Xiang, Boqing Ou

Objective: This paper was performed to decipher the serum microRNA (miR)-125b-5p expression in patients with dilated cardiomyopathy (DCM) combined with heart failure (HF) and its effect on myocardial fibrosis.

Methods: Serum miR-125b-5p expression, LVEDD, LVESD, LVEF, LVFS, and NT-proBNP levels were evaluated in clinical samples. A rat DCM model was established by continuous intraperitoneal injection of adriamycin and treated with miR-125b-5p agomir and its negative control. Cardiac function, serum TNF-α, hs-CRP, and NT-proBNP levels, pathological changes in myocardial tissues, cardiomyocyte apoptosis, and the expression levels of miR-125b-5p and fibrosis-related factors were detected in rats.

Results: In comparison to the control group, the case group had higher levels of LVEDD, LVESD, and NT-pro-BNP, and lower levels of LVEF, LVFS, and miR-125b-5p expression levels. Overexpression of miR-125b-5p effectively led to the improvement of cardiomyocyte hypertrophy and collagen arrangement disorder in DCM rats, the reduction of blue-stained collagen fibers in the interstitial myocardium, the reduction of the levels of TNF-α, hs-CRP, and NT-proBNP and the expression levels of TGF-1β, Collagen I, and α-SMA, and the reduction of the number of apoptosis in cardiomyocytes.

Conclusion: Overexpression of miR-125b-5p is effective in ameliorating myocardial fibrosis.

研究目的本文旨在解读扩张型心肌病(DCM)合并心力衰竭(HF)患者血清microRNA(miR)-125b-5p的表达及其对心肌纤维化的影响:方法: 评估临床样本中血清 miR-125b-5p 表达、LVEDD、LVESD、LVEF、LVFS 和 NT-proBNP 水平。通过连续腹腔注射阿霉素建立了大鼠 DCM 模型,并用 miR-125b-5p 激动剂及其阴性对照进行治疗。检测大鼠心功能、血清 TNF-α、hs-CRP 和 NT-proBNP 水平、心肌组织病理变化、心肌细胞凋亡以及 miR-125b-5p 和纤维化相关因子的表达水平:结果:与对照组相比,病例组的 LVEDD、LVESD 和 NT-pro-BNP 水平较高,而 LVEF、LVFS 和 miR-125b-5p 表达水平较低。过表达miR-125b-5p能有效改善DCM大鼠心肌细胞肥大和胶原排列紊乱,减少心肌间质蓝染胶原纤维,降低TNF-α、hs-CRP和NT-proBNP水平以及TGF-1β、胶原I和α-SMA的表达水平,减少心肌细胞凋亡数量:结论:过表达 miR-125b-5p 能有效改善心肌纤维化。
{"title":"Serum microRNA-125b-5p expression in patients with dilated cardiomyopathy combined with heart failure and its effect on myocardial fibrosis.","authors":"Yingjie Zhang, Daqing Deng, Quan Huang, Jiaru Wu, Yi Xiang, Boqing Ou","doi":"10.1080/14017431.2024.2373083","DOIUrl":"10.1080/14017431.2024.2373083","url":null,"abstract":"<p><strong>Objective: </strong>This paper was performed to decipher the serum microRNA (miR)-125b-5p expression in patients with dilated cardiomyopathy (DCM) combined with heart failure (HF) and its effect on myocardial fibrosis.</p><p><strong>Methods: </strong>Serum miR-125b-5p expression, LVEDD, LVESD, LVEF, LVFS, and NT-proBNP levels were evaluated in clinical samples. A rat DCM model was established by continuous intraperitoneal injection of adriamycin and treated with miR-125b-5p agomir and its negative control. Cardiac function, serum TNF-α, hs-CRP, and NT-proBNP levels, pathological changes in myocardial tissues, cardiomyocyte apoptosis, and the expression levels of miR-125b-5p and fibrosis-related factors were detected in rats.</p><p><strong>Results: </strong>In comparison to the control group, the case group had higher levels of LVEDD, LVESD, and NT-pro-BNP, and lower levels of LVEF, LVFS, and miR-125b-5p expression levels. Overexpression of miR-125b-5p effectively led to the improvement of cardiomyocyte hypertrophy and collagen arrangement disorder in DCM rats, the reduction of blue-stained collagen fibers in the interstitial myocardium, the reduction of the levels of TNF-α, hs-CRP, and NT-proBNP and the expression levels of TGF-1β, Collagen I, and α-SMA, and the reduction of the number of apoptosis in cardiomyocytes.</p><p><strong>Conclusion: </strong>Overexpression of miR-125b-5p is effective in ameliorating myocardial fibrosis.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2373083"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Timing of Chest Tube Removal Following Adult Cardiac Surgery: A Cluster Randomized Controlled Trial. 成人心脏手术后拔除胸管的时机:分组随机对照试验。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2023-12-19 DOI: 10.1080/14017431.2023.2294681
Ali Imad El-Akkawi, Ara Shwan Media, Niels Eykens Hjørnet, Dorthe Viemose Nielsen, Ivy Susanne Modrau

Objectives: Early chest tube removal following cardiac surgery may be associated with an increased risk of pleural or pericardial effusions following cardiac surgery. This study compares the effects of two fast-track chest tube removal protocols regarding the risk of pleural or pericardial effusions, requirement of opioids, respiratory function, and postoperative complications.

Design: Prospective non-blinded cluster-randomized study with alternating chest tube removal protocol in adult patients undergoing elective cardiac surgery. Monthly changing allocation to scheduled chest tube removal on the day of surgery (Day 0) versus removal on the 1st postoperative day (Day 1) provided no air leakage and output < 200 mL within the last four hours.

Results: A total of 527 patients were included in the study from September 1st 2020 until October 29th 2021 and randomly allocated to chest tube removal at day 0 (n = 255), and day 1 (n = 272). More than every fourth patient required drainage for pleural effusion with no significant difference between the groups. Earlier removal of chest tubes did not reduce requirement of analgesics, improve early respiratory function, or reduce postoperative complications. The study was halted for futility after halfway interim analysis showed insufficient promise of any treatment benefit.

Conclusion: Fast-track protocols with chest tube removal within the first 24 h after cardiac surgery may be associated a high rate of pleural effusions.

目的:心脏手术后尽早拔除胸管可能会增加心脏手术后胸膜或心包积液的风险。本研究比较了两种快速拔除胸管方案对胸膜或心包积液风险、阿片类药物需求、呼吸功能和术后并发症的影响:设计:前瞻性非盲群组随机研究,在接受择期心脏手术的成人患者中采用交替胸管拔除方案。如果在最后四小时内没有漏气且排气量小于 200 毫升,则每月更换一次分配,分别在手术当天(第 0 天)和术后第 1 天(第 1 天)拔除胸管:从2020年9月1日到2021年10月29日,共有527名患者参与研究,随机分配在第0天(255人)和第1天(272人)拔除胸管。超过四分之一的患者需要引流胸腔积液,但两组之间无明显差异。提早拔除胸管并不能减少镇痛药的需求、改善早期呼吸功能或减少术后并发症。中途进行的中期分析表明,没有足够的希望获得任何治疗益处,因此该研究因徒劳无益而终止:结论:在心脏手术后 24 小时内拔除胸管的快速通道方案可能会导致胸腔积液的高发生率。
{"title":"Timing of Chest Tube Removal Following Adult Cardiac Surgery: A Cluster Randomized Controlled Trial.","authors":"Ali Imad El-Akkawi, Ara Shwan Media, Niels Eykens Hjørnet, Dorthe Viemose Nielsen, Ivy Susanne Modrau","doi":"10.1080/14017431.2023.2294681","DOIUrl":"10.1080/14017431.2023.2294681","url":null,"abstract":"<p><strong>Objectives: </strong>Early chest tube removal following cardiac surgery may be associated with an increased risk of pleural or pericardial effusions following cardiac surgery. This study compares the effects of two fast-track chest tube removal protocols regarding the risk of pleural or pericardial effusions, requirement of opioids, respiratory function, and postoperative complications.</p><p><strong>Design: </strong>Prospective non-blinded cluster-randomized study with alternating chest tube removal protocol in adult patients undergoing elective cardiac surgery. Monthly changing allocation to scheduled chest tube removal on the day of surgery (Day 0) versus removal on the 1st postoperative day (Day 1) provided no air leakage and output < 200 mL within the last four hours.</p><p><strong>Results: </strong>A total of 527 patients were included in the study from September 1st 2020 until October 29th 2021 and randomly allocated to chest tube removal at day 0 (<i>n</i> = 255), and day 1 (<i>n</i> = 272). More than every fourth patient required drainage for pleural effusion with no significant difference between the groups. Earlier removal of chest tubes did not reduce requirement of analgesics, improve early respiratory function, or reduce postoperative complications. The study was halted for futility after halfway interim analysis showed insufficient promise of any treatment benefit.</p><p><strong>Conclusion: </strong>Fast-track protocols with chest tube removal within the first 24 h after cardiac surgery may be associated a high rate of pleural effusions.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2294681"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-rated health in primiparous women with congenital heart disease before, during and after pregnancy - A register study. 患有先天性心脏病的初产妇在怀孕前、怀孕期间和怀孕后的自评健康状况--一项登记研究。
IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-01 Epub Date: 2023-12-21 DOI: 10.1080/14017431.2023.2295782
Ylva Holstad, Bengt Johansson, Maria Lindqvist, Agneta Westergren, Inger Sundström Poromaa, Christina Christersson, Mikael Dellborg, Aleksandra Trzebiatowska-Krzynska, Peder Sörensson, Ulf Thilén, Anna-Karin Wikström, Annika Bay

Background. Poor maternal self-rated health in healthy women is associated with adverse neonatal outcomes, but knowledge about self-rated health in pregnant women with congenital heart disease (CHD) is sparse. This study, therefore, investigated self-rated health before, during, and after pregnancy in women with CHD and factors associated with poor self-rated health. Methods. The Swedish national registers for CHD and pregnancy were merged and searched for primiparous women with data on self-rated health; 600 primiparous women with CHD and 3062 women in matched controls. Analysis was performed using descriptive statistics, chi-square test and logistic regression. Results. Women with CHD equally often rated their health as poor as the controls before (15.5% vs. 15.8%, p = .88), during (29.8% vs. 26.8% p = .13), and after pregnancy (18.8% vs. 17.6% p = .46). None of the factors related to heart disease were associated with poor self-rated health. Instead, factors associated with poor self-rated health during pregnancy in women with CHD were ≤12 years of education (OR 1.7, 95%CI 1.2-2.4) and self-reported history of psychiatric illness (OR 12.6, 95%CI 1.4-3.4). After pregnancy, solely self-reported history of psychiatric illness (OR 5.2, 95%CI 1.1-3.0) was associated with poor self-rated health. Conclusion. Women with CHD reported poor self-rated health comparable to controls before, during, and after pregnancy, and factors related to heart disease were not associated with poor self-rated health. Knowledge about self-rated health may guide professionals in reproductive counselling for women with CHD. Further research is required on how pregnancy affects self-rated health for the group in a long-term perspective.

背景。健康妇女的孕产妇自评健康状况差与新生儿不良预后有关,但人们对患有先天性心脏病(CHD)的孕妇的自评健康状况知之甚少。因此,本研究调查了患有先天性心脏病的孕妇在怀孕前、怀孕期间和怀孕后的自评健康状况以及与自评健康状况差相关的因素。研究方法合并瑞典全国 CHD 和妊娠登记册,搜索有自评健康数据的初产妇、600 名患有 CHD 的初产妇和 3062 名匹配对照组妇女。分析方法包括描述性统计、卡方检验和逻辑回归。结果显示患有先天性心脏病的妇女在怀孕前(15.5% 对 15.8%,p = .88)、怀孕期间(29.8% 对 26.8% p = .13)和怀孕后(18.8% 对 17.6% p = .46)将自己的健康状况评为差的比例与对照组相同。没有一个与心脏病有关的因素与自评健康状况不良有关。相反,患有心脏病的妇女在怀孕期间自评健康状况差的相关因素是受教育年限≤12 年(OR 1.7,95%CI 1.2-2.4)和自述精神病史(OR 12.6,95%CI 1.4-3.4)。怀孕后,仅自述的精神病史(OR 5.2,95%CI 1.1-3.0)与自评健康状况差有关。结论患有先天性心脏病的妇女在怀孕前、怀孕期间和怀孕后的自评健康状况较差,与对照组相当,而与心脏病相关的因素与自评健康状况较差无关。有关自评健康状况的知识可指导专业人员为患有心脏病的妇女提供生殖咨询。从长远角度来看,还需要进一步研究怀孕如何影响该群体的自评健康。
{"title":"Self-rated health in primiparous women with congenital heart disease before, during and after pregnancy - A register study.","authors":"Ylva Holstad, Bengt Johansson, Maria Lindqvist, Agneta Westergren, Inger Sundström Poromaa, Christina Christersson, Mikael Dellborg, Aleksandra Trzebiatowska-Krzynska, Peder Sörensson, Ulf Thilén, Anna-Karin Wikström, Annika Bay","doi":"10.1080/14017431.2023.2295782","DOIUrl":"10.1080/14017431.2023.2295782","url":null,"abstract":"<p><p><i>Background.</i> Poor maternal self-rated health in healthy women is associated with adverse neonatal outcomes, but knowledge about self-rated health in pregnant women with congenital heart disease (CHD) is sparse. This study, therefore, investigated self-rated health before, during, and after pregnancy in women with CHD and factors associated with poor self-rated health. <i>Methods.</i> The Swedish national registers for CHD and pregnancy were merged and searched for primiparous women with data on self-rated health; 600 primiparous women with CHD and 3062 women in matched controls. Analysis was performed using descriptive statistics, chi-square test and logistic regression. <i>Results.</i> Women with CHD equally often rated their health as poor as the controls before (15.5% <i>vs.</i> 15.8%, <i>p</i> = .88), during (29.8% <i>vs.</i> 26.8% <i>p</i> = .13), and after pregnancy (18.8% <i>vs.</i> 17.6% <i>p</i> = .46). None of the factors related to heart disease were associated with poor self-rated health. Instead, factors associated with poor self-rated health during pregnancy in women with CHD were ≤12 years of education (OR 1.7, 95%CI 1.2-2.4) and self-reported history of psychiatric illness (OR 12.6, 95%CI 1.4-3.4). After pregnancy, solely self-reported history of psychiatric illness (OR 5.2, 95%CI 1.1-3.0) was associated with poor self-rated health. <i>Conclusion.</i> Women with CHD reported poor self-rated health comparable to controls before, during, and after pregnancy, and factors related to heart disease were not associated with poor self-rated health. Knowledge about self-rated health may guide professionals in reproductive counselling for women with CHD. Further research is required on how pregnancy affects self-rated health for the group in a long-term perspective.</p>","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":"58 1","pages":"2295782"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138831337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Cardiovascular Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1